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BUDD-CHIARI SYNDROME TRANSPLANT,
MESO-ATRIAL SHUNT OR COMBINED
PORTOCAVAL SHUNT WITH CAVO-ATRIAL SHUNT
ABSTRACT
Orloff, M.J. and Daily, P.O. (1992) Treatment of Budd-Chiari syndrome due to
inferior oena caoa occlusion by combinedportal and oena caval decompression. The
American Journal of Surgery; 163: 137-143.
This study concerns Budd-Chiari syndrome (BCS) caused by occlusion of the
subdiaphragmatic inferior vena cava (IVC). It describes the experimental and
clinical evaluation of the treatment of this disorder by one-stage combined portal and
vena caval decompression with a direct side-to-side portacaval shunt (PCS) and a
caval-atrial shunt (CAS) graft. BCS was produced in rats by gradual occlusion of the
suprahepatic IVC with an ameroid constrictor. When ascites and portal hyperten-
sion were established, 12 control rats survived a sham thoracolaparotomy, 16 rats
survived a mesoatrial shunt, and 16 rats survived combined PCS and CAS graft. All
control rats re-formed ascites and died within 2 months. Nine of 16 rats with
mesoatrial shunt developed graft thrombosis, re-formed ascites, and died within 2
months. In contrast, only 2 of 16 rats that underwent combined PCS and CAS
developed graft thrombosis, re-formed ascites, and died. Liver biopsies showed
reversal of severe pathologic changes in rats with patent grafts. Clinical evaluation of
combined PCS and CAS using a 20-mm ring-reinforced Gore-Tex graft has been
undertaken in five patients with BCS and ascites, hepatosplenomegaly, intense
hepatic congestion on biopsy, and angiography showing occlusion of both the IVC
and hepatic veins. All five patients were alive and well 6 months to 7.5 years
postoperatively with patent grafts, no ascites or need for diuretics, no encephalo-
pathy, normal liver function, and reversal of liver pathology. It is concluded that
combined PCS and CAS create a high-flow shunt that decompresses both the portal
system and IVC, has a low incidence of graft thrombosis, has been consistently
effective in relieving BCS caused by IVC occlusion, and appears to be superior to
mesoatrial shunt.332 HPB INTERNATIONAL
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The combination of clinical features known collectively as the Budd-Chiari syn-
drome results from obstruction to the venous drainage of the liver. There are
several causes for this but they all produce hepatic venous congestion, varying
degrees of hepato-cellular dysfunction and a rise in portal pressure. The obstruc-
tion can be anywhere between the venules of the liver and the inferior vena cava.
The natural history of the illness both in mode and speed of presentation and the
spectrum of the resulting symptoms can vary from a severe acute condition and
early death, to a chronic condition of cirrhosis, portal hypertension and bleeding
oesophageal varices, in some cases many years later.
Since the syndrome has multiple aetiologies, it is not surprising that there is no
single therapeutic approach. Unfortunately many clinicians do not seem to appre-
ciate this and many apparently different approaches have been described with
varying degrees of success since they are usually unrelated to the aetiology. These
vary from conservative, "Let’s hope it will recover spontaneously" to liver trans-
plantation. Each proponent claims success for his approach. The Second
International Conference on Budd-Chiari Syndrome debated this in Kyoto, Japan
in the autumn of 1991 and concluded that the syndrome needs logical classification
in order to propose rational treatment1.
In general there are two different pathological processes which can lead to this
syndrome: disseminated intra-hepatic veno-occlusive disease and hepatic vein and
vena cava blockage. The first affects the venules in the liver usually secondary to
exposure to some thrombogenic toxin such as plant alkaloids, cytotoxic drugs or
some myeloproliferative disorder. The second either follows thrombotic or neop-
lastic processes which occlude the lumen or cause pressure on the vessels, or results
fram an anatomical abnormality of the cava, the so called caval web. This may be
congenital or develop in early infancy, and is seen mainly in Asian patients, being
uncommon in the West.
Diagnosis, especially the acute form of the disease, must be established rapidly.
The definitive tests include liver biopsy, hepatic angiography with venous pressure
measurements or Doppler ultrasound of the cava and liver vessels. Histology will
demonstrate the classical centrilobular congestion and the imaging and pressure
measuring techniques will demonstrate obstruction to the hepatic venous flow.
Once the diagnosis of acute Budd-Chiari syndrome has been confirmed conserva-
tive management is ineffective and denying the patient interventional treatment is
dangerous. The one caveat to this is the possibility of using thrombolytic therapy in
acute veno-occlusive disease in an attempt to lyse the clot2. This certainly demands
further study especially in relation to the possible use of recombinant tissue
plasminogen activator (t-P/k). However any sign of deterioration must indicate
more aggressive treatment.
The mainstay of treatment in all cases is to provide as rapidly as possible either
relief of the obstruction or appropriate atlernative hepatic venous drainage. The
former can be achieved by surgical removal or angioplastic dilatation of any caval
or hepatic venous obstruction. The latter can be achieved by decompressing the
portal hypertension. If this can be done before major hepatic damage occurs thenHPB INTERNATIONAL 333
the congestion is relieved, any liver damage is reversible, and the subsequent
complications prevented. The paper by Dr Orloff and colleagues clearly supports
this.
If decompression is not effected early then either hepatocellular failure and
death or progression to chronic irreversible cardiac type cirrhosis will occur and
such patients will need a liver transplant. However there is no substantiated
evidence yet that liver transplantation is indicated in the absence of cirrhotic
change3.
There is much controversy regarding the method of providing adequate portal
decompression. A side-to-side portal system to infra-hepatic vena cava shunt is
effective providing there is significant pressure difference between the two systems.
If the pressure in the two systems is equal which happens when there is total
obstruction to the hepatic part of the inferior vena cava then such a shunt will be
ineffective. To overcome this it is necessary to shunt the portal blood into a venous
sytem with a lower pressure either above the obstruction or the right atrium. This
requires a long prosthetic graft which carries a high risk of subsequent thrombosis.
To address this Dr Orloff has studied in animals and later clinically a combi-
nation of a side-to-side portacaval shunt with a cavo-atrial prosthetic shunt. He
concludes this decompresses the liver and results in excellent flow in the long
prosthetic graft with a low incidence of thrombosis due to high flow rates.
Another method to overcome the problem of high infra-hepatic caval pressure is
to insert an expanding stent into the compressed or occluded part of the vessel4.
This will restore caval blood flow, reduce the infrahepatic caval pressure and allow
a subsequent side-to-side portacaval shunt to be constructed effectively without the
need for a long prosthesis.
Unfortunately there are no controlled studies comparing the various decompres-
sion procedures either with each other or with liver transplantation. At the Third
International Symposium on Budd-Chiari Syndrome to be held in London next
year it is planned to discuss classification of the syndrome. Hopefully then rational
treatment for each group of patients will be proposed and prospective studies of
different treatment modalities will be possible.
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